News | Radiopharmaceuticals and Tracers | January 23, 2024

Successful completion of contractual site acceptance tests, with 70 MeV cyclotron now fully operational

Successful completion of contractual site acceptance tests, with 70 MeV cyclotron now fully operational

January 23, 2024 — IBA, a world leader in particle accelerator technology and the world’s leading provider of radiopharmaceutical production solutions, is pleased to announce that the Cyclone 70 system installed at the iThemba Laboratory for Accelerator Based Sciences (iThemba LABS) in Cape Town, one of the research facilities of the National Research Foundation of South Africa, has been fully commissioned enabling iThemba LABS to start transferring the production of radioisotopes from their existing accelerator to the new Cyclone 70 system. 

Acceptance testing was completed in December 2023, with the cyclotron reaching full beam power (750µA) at full energy. This 70 MeV cyclotron will be dedicated to the production of next-generation medical isotopes used mainly in the diagnosis of critical illnesses. The machine will be used primarily for the manufacture of Strontium-82 for use in the diagnosis of cardiovascular disease, as well as for production of Germanium-68 for use in positron emission tomography (PET) imaging. 

Dr Le Roux Strydom, Head of Accelerator Operations & Technical Support at iThemba LABS, said: “We are extremely pleased with the outcome of this project. The project management was exceptional and having direct access to IBA’s experts added significant value to our experience. Our confidence in IBA’s high energy systems has been solidified by their demonstrated expertise, particularly with the 70 MeV cyclotron. We eagerly anticipate our continued collaboration with IBA, a proven leader in cyclotron technology.” 

Bruno Scutnaire, President at IBA RadioPharma Solutions, added: “We are proud to announce yet another demonstration of our expertise in 70 MeV machines with this project, with installation successfully completed and iThemba LABS ready to start the production of Strontium-82 and other radioisotopes. This latest accomplishment strengthens our leading position in cyclotron technology and attests to our commitment to delivering cutting-edge solutions to meet our clients’ needs. To date, six Cyclone® 70 MeV machines and over 35 cyclotrons of 30 MeV have been installed worldwide. We see a growing interest for these high energy machines, driven by an increasing number of clinical trials exploring new diagnostic or radiotherapeutic molecules.” 

For more information: www.iba-worldwide.com 


Related Content

News | Treatment Planning

May 6, 2024 — Elekta announced the acquisition of Philips Healthcare’s Pinnacle Treatment Planning System (TPS) patent ...

Time May 06, 2024
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

One on One interviews with radiology trailblazers and historic FDA clearances made the top-read list for April. Take a ...

Time May 03, 2024
arrow
Feature | Radiation Dose Management | By Christine Book

Advances in the growing radiation dose management market are continually helping those who administer treatment to focus ...

Time May 03, 2024
arrow
News | Artificial Intelligence

May 2, 2024 — Radformation, Inc., a leader in automation solutions for cancer care, announced today that it has acquired ...

Time May 02, 2024
arrow
News | Prostate Cancer

May 2, 2024 — GT Medical Technologies, Inc. (GT MedTech), a medical device company with the mission of improving the ...

Time May 02, 2024
arrow
News | Proton Therapy

April 29, 2024 — Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today ...

Time April 29, 2024
arrow
News | FDA

April 29, 2024 — The U.S. Food and Drug Administration (FDA) announced Elekta Instrument AB is recalling Disposable ...

Time April 29, 2024
arrow
News | Radiation Dose Management

April 25, 2024 — BIOTRONIK, a leading global medical technology company specializing in innovative cardiovascular and ...

Time April 25, 2024
arrow
News | Radiation Therapy

April 18, 2024 — Accuray Incorporated announced that as part of its commitment to advancing patient care the company has ...

Time April 18, 2024
arrow
News | FDA

April 18, 2024 — Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging ...

Time April 18, 2024
arrow
Subscribe Now